Photoactivatable Nanoparticles for Targeted Drug Delivery


The invention relates to novel lipid-based nanoparticles (liposomes) for use in targeted drug delivery. The particles include a wall surrounding a cavity, wherein the wall includes (i) a lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), and dipalmitoylphosphatidylcholine (DPPC), and (ii) a tetrapyrollic photosensitizer, such as 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer. The lipid bilayer may include one or more segregated regions, or pockets, of DC8,9PC with the HPPH being preferentially located within the DC8,9PC pockets. The nanoparticles include at least one therapeutic agent within the cavity. Upon a targeted application of light in the near-infrared range, the particles are disrupted and can release the therapeutic agent at a targeted site. The concurrent release of the photosensitizing agent HPPH may be advantageous in the treatment of certain cancers, since this agent has shown to possess therapeutic ability on its own right.

Potential Commercial Applications: Competitive Advantages:
  • The nanoparticles can be used for targeted drug delivery.
 
  • The particles are stable and can be activated upon demand to release the therapeutic agent at the desired site.
  • The concurrent release of the photosensitizing agent HPPH may be advantageous in the treatment of certain types of cancer, since this agent has shown to possess therapeutic ability on its own right.


Inventors:
Robert Blumenthal (NCI)
Anu Puri (NCI)
Amit Joshi
Darayash Tata (FDA)


Intellectual Property:
US Application No. 61/845,861

Publications:
Yavlovich A, et al. PMID 20160877
Yavlovich A, et al. PMID 20691151
Puri A, Blumenthal R. PMID 21919465
Puri A, et al. PMID 22053903

Collaboration Opportunity:

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize photoactivable nanoparticles for drug delivery. For collaboration opportunities, please contact John D. Hewes, Ph.D. at hewesj@mail.nih.gov.


Licensing Contact:
Uri Reichman , Ph.D., M.B.A.
NIH Office of Technology Transfer
Email: reichmau@mail.nih.gov
Phone: 301-435-4616

OTT Reference No: E-482-2013/0

Updated: Sep-10-2013